Dupilumab not linked to short-term cancer development in patients with atopic dermatitis

Patients with atopic dermatitis treated with dupilumab did not experience any significantly increased risk for a primary or recurrent malignancy, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.“A common question that comes up is whether the biologics that we routinely use in clinical practice, such as dupilumab, are safe in this

Read the full article here

Related Articles